154 related articles for article (PubMed ID: 34544944)
21. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
22. [A case of lenvatinib therapy-induced unilateral interstitial pneumonia and cavity formation in advanced liver cancer].
Liu SQ; Zhang XJ; Xue Y; Lu JC; Liu LG
Zhonghua Gan Zang Bing Za Zhi; 2021 Nov; 29(11):1109-1110. PubMed ID: 34933432
[TBL] [Abstract][Full Text] [Related]
23. Lenvatinib: A Review in Hepatocellular Carcinoma.
Al-Salama ZT; Syed YY; Scott LJ
Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651
[TBL] [Abstract][Full Text] [Related]
24. [A Case of Advanced Hepatocellular Carcinoma That Caused Rapid Re-Growth Due to Lenvatinib Withdrawal].
Oyama K; Maeda S; Nakahira S; Kitagawa A; Ushimaru Y; Ohara N; Miyake Y; Makari Y; Nakata K; Fujita J
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1586-1588. PubMed ID: 35046264
[TBL] [Abstract][Full Text] [Related]
25. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
26. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report.
Kohya R; Sugiura R; Yamamoto Y; Naruse H; Hatanaka K; Kinoshita K; Abiko S; Miyamoto S; Suzuki K; Kushibiki H; Munakata S; Shimoyama N
Intern Med; 2023 Apr; 62(7):995-998. PubMed ID: 36047124
[TBL] [Abstract][Full Text] [Related]
28. Minimal impact of lenvatinib (Lenvima®) on muscle mass in advanced hepatocellular carcinoma and implications for treatment duration. Two cases from the REFLECT study.
Rinninella E; Cintoni M; Raoul P; Mele MC; De Gaetano AM; Marini MG; Mora V; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):10132-10138. PubMed ID: 31799685
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma.
Ikeda A; Aoki K; Kawamura M; Yamaguchi D; Kokuryu H
Intern Med; 2021; 60(3):403-407. PubMed ID: 33518611
[TBL] [Abstract][Full Text] [Related]
30. A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma.
Bai Y; Hu X; Ren Z; Hisai T; Yusa W; Weng L; Shiba S; Takase T
Future Oncol; 2022 Jul; 18(22):2413-2424. PubMed ID: 35674480
[TBL] [Abstract][Full Text] [Related]
31. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
32. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
33. A spontaneous rupture of lung metastasis from hepatocellular carcinoma after the introduction of lenvatinib.
Higashino M; Sugiura R; Yamamoto Y; Naruse H; Sakamoto N
J Gastrointestin Liver Dis; 2021 Mar; 30(1):169-170. PubMed ID: 33723551
[No Abstract] [Full Text] [Related]
34. [A Case of Unresectable Hepatocellular Carcinoma Treated using Lenvatinib and Conversion Surgery].
Utsunomiya T; Sakamoto K; Iwata M; Ito C; Sakamoto A; Matsui T; Shine M; Nishi Y; Uraoka M; Nagaoka T; Tamura K; Funamizu N; Ogawa K; Kitazawa R; Takada Y
Gan To Kagaku Ryoho; 2022 Dec; 49(12):1365-1367. PubMed ID: 36539251
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
[TBL] [Abstract][Full Text] [Related]
36. Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma.
Okubo H; Ando H; Ishizuka K; Kitagawa R; Okubo S; Saito H; Kokubu S; Miyazaki A; Ikejima K; Shiina S; Nagahara A
PLoS One; 2020; 15(3):e0229772. PubMed ID: 32126131
[TBL] [Abstract][Full Text] [Related]
37. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
[TBL] [Abstract][Full Text] [Related]
38. Lenvatinib-Induced Tumor-Related Hemorrhage in Patients With Unresectable Hepatocellular Carcinoma.
Kotani K; Uchida-Kobayashi S; Yoshida K; Kawamura E; Fujii H; Hagihara A; Enomoto M; Tamori A; Kawada N
Am J Gastroenterol; 2021 Apr; 116(4):631. PubMed ID: 33982923
[No Abstract] [Full Text] [Related]
39. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
[TBL] [Abstract][Full Text] [Related]
40. Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma.
Ishizaki M; Kaibori M; Matsushima H; Kosaka H; Matsui K; Sekimoto M
Clin J Gastroenterol; 2021 Dec; 14(6):1700-1705. PubMed ID: 34480729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
